TOCILIZUMAB
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
TOCILIZUMAB (12761P)
12761P
Manner of administration:Injection
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another
biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 4 | # of repeats: 3 | DPMQ: $801.70 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Actemra ACTPen | |||||